Strides Arcolab has received the ANDA approval for Rifampicin injections in the strengths of 600 mg/vial, the pharma firm said in a filing to the Bombay Stock Exchange.
The product is licensed to Akorn-Strides LLC, a joint venture formed in 2004 between the US-based Akorn Inc and Strides Arcolab.
"These approvals reflect yet another milestone for the Akorn-Strides partnership which now has the approvals for seven sterile injectable products," Strides Arcolab Vice-Chairman Arun Kumar said.
Shares of Strides Arcolab closed at Rs 172 at the BSE, down 2.85 per cent from the previous close.
